Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow MIRM
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
51.96 | 116.66 | 231.82 | 156.54 | 151.72 | 286.33 | 280.32 | 383.33 |
Receivables |
— | — | — | 3.27 | 23.99 | 67.97 | 78.29 | 123.33 |
Inventory |
— | — | — | 1.51 | 5.57 | 22.31 | 22.40 | 24.89 |
Total current assets |
51.98 | 119.36 | 236.35 | 166.59 | 190.23 | 387.54 | 392.79 | 549.68 |
Property, Plant, Equpment (Net) |
— | 1.37 | 1.29 | 0.98 | 0.91 | 0.71 | 1.14 | 1.86 |
Long-Term Investments |
— | 23.29 | — | 4.98 | 100.00 | — | 12.53 | 8.11 |
Goodwill and Intangible Assets (Total) |
— | — | — | 18.74 | 58.95 | 252.93 | 249.82 | 260.92 |
Long-term assets (Other) |
— | 0.32 | 1.27 | 101.79 | 101.38 | 4.17 | 5.81 | 13.50 |
Total non-current assets |
— | 27.35 | 4.51 | 128.06 | 162.68 | 259.08 | 277.97 | 293.13 |
Total Assets |
51.98 | 146.71 | 240.86 | 294.65 | 352.91 | 646.62 | 670.75 | 842.81 |
Accounts Payable |
0.27 | 3.35 | 3.15 | 9.17 | 8.69 | 7.42 | 14.62 | 9.61 |
Accrued Expenses |
2.18 | 9.33 | 13.41 | 30.72 | 54.02 | 78.54 | 111.93 | 196.19 |
Other current liabilities |
2.18 | 9.33 | 1.26 | 2.00 | 1.09 | — | — | — |
Total current liabilities |
2.45 | 13.08 | 18.46 | 42.60 | 64.73 | 87.06 | 126.55 | 205.80 |
Long Term Debt (Total) |
— | 3.25 | 50.28 | 131.83 | 141.61 | 306.42 | 308.08 | 309.80 |
Liabilities (Preferred Stock) |
59.85 | — | — | — | — | — | — | — |
Non-current Liabilities (Other) |
6.99 | 0.04 | 47.68 | 129.94 | 144.88 | 3.85 | 2.51 | 5.01 |
Total non-current liabilities |
66.84 | 3.29 | 50.31 | 131.84 | 146.14 | 310.89 | 318.56 | 322.32 |
Total liabilities |
69.29 | 16.36 | 68.77 | 174.44 | 210.87 | 397.95 | 445.11 | 528.12 |
Additional Paid In Capital |
0.03 | 200.12 | 345.18 | 377.40 | 535.07 | 803.26 | 870.19 | 981.88 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Retained Earnings |
(17.35) | (69.90) | (173.17) | (257.16) | (392.82) | (556.24) | (644.18) | (667.54) |
Common Equity (Total) |
(17.31) | 130.35 | 172.10 | 120.21 | 142.04 | 248.67 | 225.64 | 314.69 |
Shareholders Equity (Total) |
(17.31) | 130.35 | 172.10 | 120.21 | 142.04 | 248.67 | 225.64 | 314.69 |
Shareholders Equity and Liabilities (Total) |
51.98 | 146.71 | 240.86 | 294.65 | 352.91 | 646.62 | 670.75 | 842.81 |
Shares (Common) |
0.64 | 22.60 | 29.78 | 30.58 | 36.96 | 46.72 | 48.34 | 51.90 |
Shareholders Equity (Tangible) |
(17.31) | 130.35 | 172.10 | 101.47 | 83.08 | (4.25) | (24.18) | 53.77 |
Net Debt |
(51.96) | (113.41) | (181.54) | (24.71) | (10.11) | 20.10 | 27.77 | (73.53) |
Total Debt |
— | 3.25 | 50.28 | 131.83 | 141.61 | 306.42 | 308.08 | 309.80 |